Strategic human raw material selection for cell therapy manufacturing

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Strategic human raw material selection for cell therapy manufacturing

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Learn how strategic choices in human raw materials, automation, and supplier selection can drive the success and scalability of CAR-T cell therapies. This webinar will reveal how a focus on cost-effective, high-quality academic manufacturing models can deliver accessible and effective treatments without compromising safety or efficacy. By optimizing human raw material selection and ensuring regulatory compliance from early development stages, manufacturers can streamline approvals, enhance cell performance, and reduce risk.

Daniel Benítez (Qualified Person, Immunotherapy Dept., Hospital Clínic de Barcelona) will share insights from the ARI-0001 therapy manufacturing process, highlighting how the use of human raw materials plays a critical role in ensuring consistent, high-performing CAR-T cell production. Attendees will also explore how automation in cell therapy manufacturing helps reduce manual variability and operational risk, resulting in a more efficient and scalable workflow.

Additionally, the webinar will cover how working with reliable suppliers can simplify the path to approval and support the transition from clinical to commercial manufacturing. Participants will gain insights into practical guidance on supplier qualification, regulatory expectations, and strategies for integrating high-quality raw materials to boost therapeutic outcomes.

Attend this webinar to:

Learn how high-quality, well characterized human raw materials contribute to enhanced cell growth, consistency, and safety in CAR-T manufacturing
Explore how automating cell therapy production reduces manual error, improves reproducibility, and helps scale therapies efficiently
Understand what to look for in a human raw material supplier to ensure regulatory compliance, scalability, and a smoother path to market approval

Daniel Benitez-Ribas

Qualified Person, Immunotherapy Dept. at Hospital Clínic de Barcelona

Dr Daniel Benítez Ribas is the Qualified Person of the Immunotherapy Section (Immunology Department), responsible for ensuring the quality of cell therapies, including CAR-T cells such as ARI-0001 (Varnimcabtagene autoleucel) and ARI-0002h (Cesnicabtagene autoleucel) both approved by the AEMPS and produced under GMP regulations.

He obtained his Bachelor’s degree in Biology from the University of Barcelona in 1995 and completed his PhD at the Immunology Service of HCB in 2003. He conducted his postdoctoral research at Radboud University, Nijmegen, Netherlands, where he developed dendritic cell vaccines for metastatic melanoma. In 2008, he joined CIBERehd as a Principal Investigator at Hospital Clínic de Barcelona, supervising dendritic cell-based therapies for autoimmune diseases, including the first Phase Ib clinical trial in humans for Crohn’s disease. Since 2016, he has been part of the Immunology Dept. at Hospital Clínic de Barcelona and IDIBAPS, focusing on cell-based therapies for cancer and autoimmune diseases, and overseeing several clinical trials. He has published over 135 articles in renowned journals and holds two patents, participating in numerous antitumor immunotherapy projects.